The VEGF +405 G>C 5' untranslated region polymorphism and risk of PCOS: a study in the South Indian Women

Journal of Assisted Reproduction and Genetics

Volumn 31, Issue 10, 2014, Pages 1383-1389

  Guruvaiah, Praveen ^a   Govatati, Suresh ^a   Reddy, Tumu Venkat ^a   Lomada, Dakshayani ^b   Deenadayal, Mamata ^c   Shivaji, Sisinthy ^d,e   Bhanoori, Manjula ^a  

^a OSMANIA UNIVERSITY   (India)

^b YOGI VEMANA UNIVERSITY   (India)

^c Infertility Institute and Research Centre (IIRC)   (India)

^d CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^e L V PRASAD EYE INSTITUTE   (India)

Author keywords

Haplotype; PCOS; SNP; South Indian women; VEGF

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; VASCULOTROPIN; 5' UNTRANSLATED REGION; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

5' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; FOLLITROPIN BLOOD LEVEL; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; HAPLOTYPE; HOMOZYGOTE; HUMAN; INDIAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; RISK; RISK FACTOR;

5' UNTRANSLATED REGIONS; ADULT; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84918798075     PISSN: 10580468     EISSN: 15737330     Source Type: Journal    
DOI: 10.1007/s10815-014-0310-4     Document Type: Article

References (31)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endcrinol Met. 2004;89:2745–9.
2. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenisis and diagnosis. Nat Rev Endocrinol. 2011;7:219–31.
3. De Vries MJ, Dekker GA, Schoemaker J. Higher risk of preeclampsia in the polycystic ovary syndrome. a case control study. Eur J Obstet Gynecol Reprod Biol. 1998;76:91–5.
4. Garelli S, Masiero S, Plebani M, et al. High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):248–51.
5. Pan HA, Wu MH, Cheng YC, Li CH, Chang FM. Quantification of Doppler signal in polycystic ovary syndrome using three-dimensional power Doppler ultrasonography: a possible new marker for diagnosis. Hum Reprod. 2002;17:201–6.
6. Agrawal R, Tan SL, Wild S, Conway G. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril. 1999;71:287–93.
7. Van Blerkom J, Antezak M, Schrader R. The development potential of the human oocyte is related to the dissolved oxygen content of follicular fluid: association with vascular endothelial growth factor levels and perifollicular blood flow characteristics. Hum Reprod. 1997;12:1047–55.
8. Agrawal R, Jacobs H, Payne N, Conway G. Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovaries. Fertil Steril. 2002;78:1164–9.
9. Abd El Aal DE, Mohamed SA, Amine AF, Meki AR. Vascular endothelial growth factor and insulin-like growth factor1 in polycystic ovary syndrome and their relation to ovarian blood flow. Eur J Obstet Gynecol Reprod Biol. 2005;118(2):219–24.
10. Ferrara N, Frantz G, LeCounter J, Dillard-Telm L, Pham T, Draksharapu A, et al. Differential expression of the angiogenic factor genes vascular endothelial groeth factor (VEGF) and endocrine gland- derived VEGF in normal and polycystic human ovaries. Am J Pathol. 2003;162:1881–92.
11. Lowenstein L, Damti A, Pillar G, Shott S, Blumenfeld Z. Evalution of endothelial function in women with polycystic ovary syndrome. Eur J Obstet Gyncol Reprod Biol. 2007;134:208–12.
12. Balen AH. Hyper secretion of luteinizing hormone in the polycystic ovary syndrome and a novel hormone ‘gonadotrophin surge attenuating factor’. J R Soc Med. 1995;88(6):339P–41P.
13. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12:1232–5.
14. Wang K, Liu L, Zhu ZM, Shao JH, Xin L. Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer. a meta-analysis involving 16,703 individuals. Cytokine. 2011;56:167–73.
15. Bhanoori M, Babu KA, Reddy NGP, et al. The vascular endothelial growth factor (VEGF) + 405G>C 5’-untranslatedregion polymorphism and increased risk of endometriosis in South Indian women: a case control study. Hum Reprod. 2005;20:1844–9.
16. Tumu VR, Govatati S, Guruvaiah P, Deenadayal M, Shivaji S, Bhanoori M. An interleukin-6 gene promoter polymorphism is associated with polycystic ovary syndrome in South Indian women. J Assist Reprod Genet. 2013;30(12):1541–6.
17. Govatati S, Tangudu NK, Deenadayal M, Chakravarty B, Shivaji S, Bhanoori M. Association of E-cadherin single nucleotide polymorphisms with the increased risk of Endometriosis in Indian women. Mol Hum Reprod. 2012;18(5):280–87.
18. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.
19. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.
20. Vural P, Baki M, Doğru-Abbasoğlu S, Özderya A, Karadağ B, Uysal M. Vascular endothelial growth factor polymorphisms increase the risk of developing graves’ disease. Int Immunopharmacol. 2012;14:133–7.
21. Summers AM, Coupes BM, Brennan MF, Ralph SA, Short CD, Brenchley PE. VEGF −460 genotype plays an important role in progression to chronic kidney disease stage 5. Nephrol Dial Transplant. 2005;20:2427–32.
22. Vural P, Küskü-Kiraz Z, Doğru-Abbasoğlu S, Cil E, Karadağ B, Akgül C, et al. Vascular endothelial growth factor −2578 A/C,-460 T/C and +405 G/C polymorphisms in polycystic ovay syndrome. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):57–60.
23. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996;93:1493–5.
24. Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O, Levi BZ. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene. 1998;17:227–36.
25. Shahbazi M, Fryer AA, Pravica V. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2002;13:260–4.
26. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic vascular endothelial growth factor gene promoter. Cancer Res. 2003;63:812–6.
27. Aleem FA, Predanic M. Transvaginal color Doppler determination of the ovarian and uterine blood flow characteristics in polycystic ovary disease. Fertil Steril. 1996;65(3):510–6.
28. Solomon CG. The epidemiology of polycystic ovary syndrome: prevalence and associated disease risks. Endocrinol Metab Clin North Am. 1999;28:247–63.
29. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res. 2000;60(12):3183–90.
30. Hu Y, Ghosh S, Amleh A, et al. Modulation of aromatase expression By BRCA1: a possible link to tissue-specific tumor suppression. Oncogene. 2005;24:8343–8.
31. Kawai H, Li H, Chun F, Avraham S, Avraham HK. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene. 2002;21:7730–9.